Rosetta Genomics Financial Statements
Rosetta Genomics Financial Information
| Company Type | Public Single Location |
|---|---|
| Fiscal Year-End | December |
This data is provided as per license from EDGAR Online
Rosetta Genomics Income Statement
| 2007 | 2006 | 2005 | |
|---|---|---|---|
| Revenue ($ mil.) | 0.0 | 0.0 | 0.0 |
| Gross Profit ($ mil.) | -- | -- | -- |
| Operating Income ($ mil.) | (11.0) | (8.1) | (5.2) |
| Total Net Income ($ mil.) | (14.7) | (7.6) | (5.8) |
| Diluted EPS (Net Income) | (1.32) | 2.98 | (2.35) |
Rosetta Genomics Stock Quote & Chart
08/21/08 14:36:15 EST •
NASDAQ •
3.64
•
 -0.1741
•
-4.5694 %
|
|---|
|
Quotes delayed 15 minutes for NASDAQ. 20 minutes for NYSE and AMEX. Market Data provided by Interactive Data. Powered and Implemented by Interactive Data Managed Solutions.
|
Rosetta Genomics Financial Ratios
| Company | Industry Median |
Market Median1 |
|
|---|---|---|---|
| Price/Sales Ratio | -- | 3.69 | 1.54 |
| Price/Earnings Ratio | -- | 15.22 | 15.51 |
| Price/Book Ratio | 2.24 | 2.94 | 1.48 |
| Price/Cash Flow Ratio | -- | 12.49 | 9.68 |
1 Public companies trading on the New York Stock Exchange, the American Stock Exchange, and the NASDAQ National Market.
Detailed Rosetta Genomics Financial Ratios
Rosetta Genomics Competitive Intelligence
| Alnylam | Isis Pharmaceuticals | Merck | |
|---|---|---|---|
| Annual Sales ($ mil.) | 50.9 | 69.6 | 24,197.7 |
| Employees | -- | -- | 59,800 |
| Market Cap ($ mil.) | 1,416.1 | 1,712.3 | 75,522.2 |
Competitive Landscape
